Clinical trials
catalyst calendar across sponsors →Studies where CNTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 with posted results
Held by 9 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, MARSHALL WACE, LLP, Qube Research & Technologies Ltd, MILLENNIUM MANAGEMENT LLC, +4 more) · FINRA short interest 4.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersNCT07545122Phase 1a: Incidence of Dose Limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CT-202 | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | 162 | Jan 2030 | ≤ 1,260 d | 2026-08-18 |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsNCT06515613Incidence of Dose Limiting Toxicities (DLTs)Open-label · Treatment | Phase 1 | Recruiting | Drug: CTIM-76 | Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer | 156 | 2028-05-31 | in 650 d | 2026-06-16 |
| CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035Determine the MTD or RD of CT-95 [Safety and Tolerability]Open-label · Treatment | Phase 1 | Recruiting | Drug: CT-95 | Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable, Mesothelin-expressing Advanced Cancers, Mesothelin-positive Advanced Malignant Solid Tumors, Colorectal Cancer | 70 | Dec 2026 | ≤ 133 d | 2026-06-12 |
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast CancerNCT06938711Characterize the safety of elacestrant in combination with onapristone.Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Change in corporate strategy. | Drug: Elacestrant, Onapristone | Breast Cancer | 0 | Nov 2023 | — | 2025-04-22 |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast CancerNCT05618613results2026-07-21Number of Participants With Dose-Limiting Toxicities (DLTs) During First CycleOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision to discontinue onapristone development. | Drug: Elacestrant, Onapristone | Breast Cancer | 4 | 2023-06-23actual | — | 2026-07-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19